3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
9
Neoplasms
4
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
2
Ipilimumab
2
Doxorubicin
2
soblidotin
1
reolysin
1
olaratumab
1
futibatinib
1
envafolimab
1
brigimadlin
1
belinostat
1
Injections
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Histamine H2 Antagonists
1
Gemcitabine
1
Fluorouracil
1
Famotidine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Histiocytoma, Malignant Fibrous
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts